Analyst Price Target is $8.00
▲ +4,238.39% Upside Potential
This price target is based on 0 analysts offering 12 month price targets for ReShape Lifesciences in the last 3 months. The average price target is $8.00, with a high forecast of $8.00 and a low forecast of $8.00. The average price target represents a 4,238.39% upside from the last price of $0.18.
Current Consensus is
N/A
The current consensus among 0 polled investment analysts is to n/a stock in ReShape Lifesciences. This N/A consensus rating has held steady for over two years.
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy and ReShape Vest system, a laparoscopically implantable device to enable weight loss and stomach preservation. It also offers ReShapeCare virtual health coaching program, a program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.
Read More